Notice NOT-DA-21-078 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-027 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-22-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to maintain the Data Coordinating Center (DCC) for the Caenorhabditis Intervention Testing Program (CITP,) to coordinate data collection and analysis among the laboratories participating in the CITP, and to provide public access to standard operating procedures and experimental outcomes (including an accessible, annotated, and user-friendly database). The purpose of the CITP is to test, under standardized conditions at a consortium of three sites, potential intervention strategies that may moderate/alleviate health declines associated with aging across genetically diverse species and strains of Caenorhabditis. The CITP will continue to use lifespan and indicators of locomotory health as criteria for efficacious impact by targeting mechanisms likely to be conserved across phyla, but will combine compound sets derived from multiple sources, including those proposed by the biology of aging research community. The goals of next phase of the CITP are to: 1) increase the capacity to screen compounds with a high standard of rigor and reproducibility; 2) evaluate and, if warranted, implement new technologies, protocols, and genetic models of Caenorhabditis to enhance the throughput and depth of the CITP; 3) measure transcriptomic profiles to provide additional information on compounds that are effective in multiple species and/or strains, or on compounds that are effective in only a subset of species or strains; 4) develop reporters of various aging hallmarks in genetically diverse Caenorhabditis strains; and 5) use identified reporters to develop phenotypic screens against hallmarks of aging as a novel paradigm for anti-aging compounds that can have multiple uses in basic research as well as generate unique platforms for translational research.

Determines and performs appropriate bioinformatic analysis of data generated through high complexity techniques. Along with Flexible Spending options.
From Medical College of Wisconsin - Mon, 20 Sep 2021 21:14:43 GMT - View all Milwaukee, WI jobs

Notice NOT-DA-21-075 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-035 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-105 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

Funding Opportunity PAR-22-036 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

Notice NOT-CA-21-116 from the NIH Guide for Grants and Contracts

M.S with at least 3-5 year of industry/academic experience in data science, mathematics, computer science, physics, biostatistics, computational biology,…
From LGC Limited - Mon, 20 Sep 2021 16:35:07 GMT - View all Middleton, WI jobs

Notice NOT-EB-21-027 from the NIH Guide for Grants and Contracts

Notice NOT-DK-21-027 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-333 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

Notice NOT-DA-21-076 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-21-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that will advance the understanding of how the microbiome affects radiation injury and to develop medical countermeasures (MCMs) that target the microbiome to prevent or mitigate radiation injury.

Funding Opportunity RFA-AI-21-060 from the NIH Guide for Grants and Contracts. The purpose of the SUNBEAM - Analysis and Bioinformatics Center (SUNBEAM-ABC) is to establish a mechanistic omics center to support the birth cohort study Systems Biology of Early Atopy (SUNBEAM). The center will assay biologic samples collected within the SUNBEAM cohort using omics and systems biology approaches to identify determinants of atopic disease, focusing on food allergy and atopic dermatitis (AD) in newborns, infants, and very young children. SUNBEAM-ABC will support the SUNBEAM birth cohort study by providing analytic infrastructure for a comprehensive understanding of molecular and cellular pathways that contribute to atopic disease development and to identify early predictive biomarkers.

Notice NOT-DA-21-077 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: The Ensembl Software Infrastructure team seeks an enthusiastic Software Developer to join and contribute to the Ensembl project. Ensembl (http://www. Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: We are looking for an enthusiastic User Experience (UX) Designer to join the European Bioinformatics Institute (EMBL-EBI) in our mission to create sci Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: An exciting opportunity has been created for a talented scientific software engineer to work on the development of the ChEBI database (https://www.ebi Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: An exciting opportunity has been created for a full stack software developer to work on the development of the ChEBI database (https://www.ebi.ac.uk/c Hinxton, Cambridgeshire, England